178 related articles for article (PubMed ID: 32758364)
61. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
62. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
63. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Haibe Y; El Husseini Z; El Sayed R; Shamseddine A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867025
[TBL] [Abstract][Full Text] [Related]
64. [Current advances in immunotherapy in ovarian cancer].
Le Saux O; Dubois B; Stern MH; Terme M; Tartour E; Classe JM; Chopin N; Trédan O; Caux C; Ray-Coquard I
Bull Cancer; 2020 Apr; 107(4):465-473. PubMed ID: 32089245
[TBL] [Abstract][Full Text] [Related]
65. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
66. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
[TBL] [Abstract][Full Text] [Related]
67. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
68. Immune checkpoint inhibitors and the development of granulomatous reactions.
Cornejo CM; Haun P; English J; Rosenbach M
J Am Acad Dermatol; 2019 Nov; 81(5):1165-1175. PubMed ID: 30092327
[TBL] [Abstract][Full Text] [Related]
69. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
70. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
71. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
[TBL] [Abstract][Full Text] [Related]
72. [Specific immunotherapies in the treatment of cancers].
Denis H; Davoine C; Bermudez E; Grosjean G; Schwager M; Ifrah N; Dahan M; Negellen S
Bull Cancer; 2019 Jan; 106(1):37-47. PubMed ID: 30638899
[TBL] [Abstract][Full Text] [Related]
73. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
74. [Checkpoint inhibitors neurological side effects].
Suay G; Bataller L
Rev Neurol; 2019 Apr; 68(7):301-311. PubMed ID: 30906980
[TBL] [Abstract][Full Text] [Related]
75. [Not Available].
Simonaggio A; Marabelle A
Bull Cancer; 2018 Dec; 105 Suppl 1():S121-S131. PubMed ID: 30595193
[TBL] [Abstract][Full Text] [Related]
76. Use of Immune Checkpoint Inhibitors in Mesothelioma.
Forde PM; Scherpereel A; Tsao AS
Curr Treat Options Oncol; 2019 Feb; 20(2):18. PubMed ID: 30762130
[TBL] [Abstract][Full Text] [Related]
77. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
O'Neill RE; Cao X
Adv Cancer Res; 2019; 143():145-194. PubMed ID: 31202358
[TBL] [Abstract][Full Text] [Related]
78. Role of immune-checkpoint inhibitors in lung cancer.
Jain P; Jain C; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
[TBL] [Abstract][Full Text] [Related]
79. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
Myers G
Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
[TBL] [Abstract][Full Text] [Related]
80. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]